TCG Crossover Management
Latest statistics and disclosures from TCG Crossover Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GPCR, COGT, GERN, ANTX, SVRA, and represent 38.45% of TCG Crossover Management's stock portfolio.
- Added to shares of these 10 stocks: GPCR (+$58M), SVRA (+$38M), TSHA (+$35M), INBX (+$32M), CMPS (+$29M), ANTX (+$22M), TARS (+$20M), Rayzebio (+$19M), CNTA (+$13M), Gracell Biotechnologies (+$8.8M).
- Started 8 new stock positions in CNTA, INBX, SVRA, TARS, Rayzebio, CMPS, Gracell Biotechnologies, TSHA.
- Reduced shares in these 6 stocks: Iveric Bio (-$96M), Vectivbio Hldg (-$53M), IMVT (-$12M), ACRS (-$5.5M), ALPN, GERN.
- Sold out of its positions in ACRS, ALPN, Iveric Bio, Vectivbio Hldg.
- TCG Crossover Management was a net buyer of stock by $110M.
- TCG Crossover Management has $679M in assets under management (AUM), dropping by 11.37%.
- Central Index Key (CIK): 0001839948
Tip: Access up to 7 years of quarterly data
Positions held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for TCG Crossover Management
TCG Crossover Management holds 26 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Structure Therapeutics Adrs (GPCR) | 11.2 | $76M | +329% | 1.5M | 50.42 |
|
| Cogent Biosciences Comm (COGT) | 8.1 | $55M | 5.6M | 9.75 |
|
|
| Geron Corp Comm (GERN) | 7.3 | $50M | 23M | 2.12 |
|
|
| AN2 Therapeutics Comm (ANTX) | 6.3 | $43M | +107% | 2.7M | 16.08 |
|
| Savara Comm (SVRA) | 5.6 | $38M | NEW | 10M | 3.78 |
|
| Taysha Gene Therapies Comm (TSHA) | 5.2 | $35M | NEW | 11M | 3.16 |
|
| Kalvista Pharmaceuticals Comm (KALV) | 4.8 | $33M | 3.4M | 9.63 |
|
|
| Inhibrx Comm (INBX) | 4.7 | $32M | NEW | 1.8M | 18.35 |
|
| Aerovate Therapeutics Comm (AVTE) | 4.4 | $30M | 2.2M | 13.57 |
|
|
| Icosavax Comm | 4.2 | $29M | 3.7M | 7.75 |
|
|
| Compass Pathways Adrs (CMPS) | 4.2 | $29M | NEW | 3.9M | 7.40 |
|
| Ventyx Biosciences Comm (VTYX) | 4.2 | $28M | 816k | 34.73 |
|
|
| Tyra Biosciences Comm (TYRA) | 4.0 | $27M | 2.0M | 13.77 |
|
|
| Madrigal Pharmaceuticals Comm (MDGL) | 3.9 | $26M | +20% | 180k | 146.04 |
|
| Silence Therapeutics Adrs (SLN) | 3.0 | $21M | 2.1M | 9.82 |
|
|
| Tarsus Pharmaceuticals Comm (TARS) | 3.0 | $20M | NEW | 1.1M | 17.77 |
|
| Rayzebio Comm | 2.8 | $19M | NEW | 870k | 22.20 |
|
| Dyne Therapeutics Comm (DYN) | 2.2 | $15M | 1.7M | 8.96 |
|
|
| Centessa Pharmaceuticals Comm (CNTA) | 1.9 | $13M | NEW | 2.0M | 6.47 |
|
| Kura Oncology Comm (KURA) | 1.9 | $13M | 1.4M | 9.12 |
|
|
| Immunovant Comm (IMVT) | 1.9 | $13M | -48% | 335k | 38.39 |
|
| Entrada Therapeutics Comm (TRDA) | 1.4 | $9.2M | 585k | 15.80 |
|
|
| Gracell Biotechnologies Adrs | 1.3 | $8.8M | NEW | 3.0M | 2.88 |
|
| Cabaletta Bio Comm (CABA) | 1.1 | $7.4M | 487k | 15.22 |
|
|
| Merus Comm (MRUS) | 1.0 | $7.1M | 300k | 23.58 |
|
|
| C4 Therapeutics Comm (CCCC) | 0.3 | $2.4M | 1.3M | 1.86 |
|
Past Filings by TCG Crossover Management
SEC 13F filings are viewable for TCG Crossover Management going back to 2021
- TCG Crossover Management 2023 Q3 filed Nov. 14, 2023
- TCG Crossover Management 2023 Q2 filed Aug. 14, 2023
- TCG Crossover Management 2023 Q1 filed May 15, 2023
- TCG Crossover Management 2022 Q4 filed Feb. 14, 2023
- TCG Crossover Management 2022 Q3 filed Nov. 14, 2022
- TCG Crossover Management 2022 Q2 filed Aug. 15, 2022
- TCG Crossover Management 2022 Q1 filed May 16, 2022
- TCG Crossover Management 2021 Q4 filed Feb. 18, 2022